Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the French colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the French colorectal cancer therapeutics market. It analyses the treatment usage patterns in the French colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the French colorectal cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized French colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020.
• Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
• Competitor assessment including drug launch analysis and drug sales forecasts.
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
• Analysis of unmet need in the market and target product profile including opportunity for target product.
• Technology trends analytic framework to assess strength of pipeline.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
• Analysis of the current and future market competition in the French Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
• Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
• Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
• Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in France.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop business strategies and perform superior market quantification analysis by
• Understanding the trends shaping and driving the French colorectal cancer therapeutics market.
• Understanding treatment preferences of physicians in disease state and across treatment flow.
• Accessing market sizing, forecasts and quantified growth opportunities in the French colorectal cancer therapeutics market till 2020.
• Quantifying patient population in France to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
• Performing benchmarking analysis and growth opportunities against currently marketed products
• Identifying market entry points based on safety, efficacy, and pricing parameters.
• Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
• Develop and design your in-licensing and out-licensing strategies by
• Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
• Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
• Track drug sales in the French colorectal cancer therapeutics market from 2001 to 2020
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the French Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.

Table Of Contents

1 Colorectal Cancer: Executive Summary
1.1 The Colorectal Cancer Therapeutics Market in France was Worth $0.7 billion in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy
1.2 The Current Competition in the Colorectal Cancer Therapeutics Market in France is Weak as None of the Drugs Completely Addressed the Unmet Needs
1.3 The Colorectal Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development
1.4 High Unmet Needs Exist in the French Colorectal Cancer Therapeutics Market in terms of Efficacy and Safety

2 Disease Overview
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Colon Cancer
2.4.2 Rectal Cancer
2.5 Diagnosis
2.5.1 FOBT
2.5.1.1 Sensitivity
2.5.2 Endoscopy
2.5.2.1 Sigmoidoscopy
2.5.2.2 Sensitivity
2.5.3 Optical Colonoscopy
2.5.3.1 Sensitivity
2.5.4 Virtual Colonoscopy
2.5.4.1 Sensitivity
2.5.5 Double Contrast Barium Enema (DCBE)
2.5.5.1 Sensitivity
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Colon Cancer Treatment by Stage
2.7.2 Rectal Cancer Treatment by Stage
2.7.3 Chemotherapy Options
2.7.3.1 Adjuvant Treatment
2.7.3.2 First-line Treatment
2.7.3.3 Second-line Treatment
2.7.3.4 Third-line Treatment
2.8 Treatment Guidelines

3 Market Characterization
3.1 France
3.1.1 Market Size
3.1.1.1 Sales Value
3.1.1.2 Annual Cost of Therapy
3.1.1.3 Patient Volume
3.1.1.4 Treatment Usage Patterns
3.1.2 Drivers and Barriers
3.1.2.1 Drivers of France Colorectal Cancer Market
3.1.2.2 Restraints of France colorectal Cancer Market
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.4.1 Sales Value
3.1.4.2 Annual Cost of Therapy
3.1.4.3 Patient Volume
3.1.4.4 Treatment Usage Patterns
3.1.4.5 Future Impact
3.1.5 Drug Sales
3.1.5.1 Overview
3.1.6 Pricing & Reimbursements
3.1.6.1 Pricing of Drugs in France
3.1.6.2 Reimbursement Policy in France
3.2 Key Takeaway

4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.2.1 Clinical Endpoints Benchmarking
4.1.2.2 Safety Profile
4.1.2.3 Annual Cost of Therapy
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.2.1 Market Share Analysis of Drugs
4.3 Product Profiles
4.3.1 Avastin (bevacizumab)
4.3.1.1 Overview
4.3.1.2 Efficacy
4.3.1.3 Safety
4.3.1.4 Clinical Study Details
4.3.1.5 Annual Cost of Therapy
4.3.1.6 Regulatory Approvals
4.3.1.7 Life Cycle Management Activities
4.3.1.8 Product Positioning
4.3.1.9 Sales Forecast
4.3.2 Erbitux (cetuximab)
4.3.2.1 Overview
4.3.2.2 Efficacy
4.3.2.3 Safety
4.3.2.4 Clinical Study Details
4.3.2.5 Annual Cost of Therapy
4.3.2.6 Regulatory Approvals
4.3.2.7 Life Cycle Management Activities
4.3.2.8 Product Positioning
4.3.2.9 Sales Forecast
4.3.3 Xeloda (capecitabine)
4.3.3.1 Overview
4.3.3.2 Efficacy
4.3.3.3 Safety
4.3.3.4 Clinical Study Details
4.3.3.5 Regulatory Approvals
4.3.3.6 Life Cyle Management Activities
4.3.3.7 Annual Cost of Therapy
4.3.3.8 Product Positioning
4.3.3.9 Sales Forecast
4.3.4 Vectibix (panitumumab)
4.3.4.1 Overview
4.3.4.2 Efficacy
4.3.4.3 Safety
4.3.4.4 Clinical Study Details
4.3.4.5 Regulatory Approvals
4.3.4.6 Life Cyle Management Activities
4.3.4.7 Annual Cost of Therapy
4.3.4.8 Product Positioning
4.3.4.9 Sales Forecast
4.3.5 Eloxatin (oxaliplatin)
4.3.5.1 Overview
4.3.5.2 Efficacy
4.3.5.3 Safety
4.3.5.4 Clinical Study Details
4.3.5.5 Regulatory Approvals
4.3.5.6 Life Cyle Management Activities
4.3.5.7 Annual Cost of Therapy
4.3.5.8 Product Positioning
4.3.5.9 Sales Forecast
4.3.6 Camptosar (irinotecan)
4.3.6.1 Overview
4.3.6.2 Efficacy
4.3.6.3 Safety
4.3.6.4 Clinical Study Details
4.3.6.5 Annual cost of Therapy
4.3.6.6 Regulatory approvals
4.3.6.7 Life Cyle Management Activities
4.3.6.8 Sales forecast
4.3.7 Fluorouracil (5-FU)
4.3.7.1 Overview
4.3.7.2 Efficacy
4.3.7.3 Safety
4.3.7.4 Annual Cost of Therapy
4.3.8 Leucovorin (folinic acid)
4.3.8.1 Overview
4.3.8.2 Efficacy
4.3.8.3 Safety
4.3.8.4 Annual Cost of Therapy
4.4 Key Takeaway

5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Colorectal Cancer Pipeline
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline
5.5.3 Failure of key Molecules in Phase II and Phase III Development
5.6 Partners in Development
5.6.1 Licensing Agreements by Phase of Development
5.6.1.1 Morphotek Enters Into Exclusive License Agreement with National Cancer Institute
5.6.1.2 AVEO Pharmaceuticals Enters Into Licensing Agreement with Kirin Brewery
5.6.1.3 Access Pharmaceuticals Enters Into Licensing Agreement with Jiangsu Aosaikang Pharmaceutical
5.6.1.4 Merck Enters Into Licensing Agreement with Taiho Pharmaceutical
5.6.1.5 Rexahn Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical
5.6.1.6 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
5.7 Most Promising Drugs’ Profiles
5.7.1 Aflibercept
5.7.1.1 Overview
5.7.1.2 Efficacy
5.7.1.3 Safety
5.7.1.4 Clinical Study Details
5.7.1.5 Collaboration Agreements
5.7.1.6 Marketing Rights
5.7.1.7 Launch Analysis
5.7.1.8 Sales Forecast
5.7.2 Brivanib
5.7.2.1 Overview
5.7.2.2 Efficacy
5.7.2.3 Safety
5.7.2.4 Clinical trials
5.7.2.5 Collaboration Agreements
5.7.2.6 Marketing Rights
5.7.2.7 Launch Analysis
5.7.2.8 Sales Forecast
5.7.3 OncoVAX
5.7.3.1 Overview
5.7.3.2 Efficacy
5.7.3.3 Safety
5.7.3.4 Clinical Trials
5.7.3.5 Collaboration Agreements
5.7.3.6 Marketing Rights
5.7.3.7 Launch Analysis
5.7.3.8 Sales Forecast
5.7.4 TroVax
5.7.4.1 Overview
5.7.4.2 Efficacy
5.7.4.3 Safety
5.7.4.4 Clinical Study Details
5.7.4.5 Collaboration Agreements
5.7.4.6 Marketing Rights
5.7.4.7 Launch Analysis
5.7.4.8 Sales Forecast
5.7.5 KRX-0401 (Perifosine)
5.7.5.1 Overview
5.7.5.2 Efficacy
5.7.5.3 Safety
5.7.5.4 Clinical Study Details
5.7.5.5 Collaboration Agreements
5.7.5.6 Marketing Rights
5.7.5.7 Launch Analysis
5.8 Colorectal Cancer Pipeline – Preclinical Phase
5.9 Colorectal Cancer Pipeline – Phase I
5.10 Colorectal Cancer Pipeline – Phase II
5.11 Colorectal Cancer Pipeline – Phase III
5.12 Key Takeaway

6 Unmet Need
6.1 Opportunity for Target Product
6.2 Target Product Profile
6.2.1 Ideal Characteristics
6.2.2 Target Product Description
6.3 Key Takeaway

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway

8 Company Profiles
8.1 F. Hoffmann La Roche
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.3.1 Strengths
8.1.3.2 Weakness
8.1.3.3 Opportunities
8.1.3.4 Threats
8.2 Bristol-Myers Squibb
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.3.1 Strengths
8.2.3.2 Weakness
8.2.3.3 Opportunities
8.2.3.4 Threats
8.3 Sanofi-Aventis
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.3.1 Strengths
8.3.3.2 Weakness
8.3.3.3 Opportunities
8.3.3.4 Threats
8.4 Debiopharm Group
8.4.1 Business Description
8.5 Merck KGaA
8.5.1 Business Description
8.5.2 Financial Overview
8.5.3 SWOT Analysis
8.5.3.1 Weakness
8.5.3.2 Opportunities
8.5.3.3 Threats
8.6 Regeneron
8.6.1 Business Description
8.6.2 Financial Overview
8.6.3 SWOT Analysis
8.6.3.1 Strengths
8.6.3.2 Weakness
8.6.3.3 Opportunities
8.6.3.4 Threats
8.7 Vaccinogen BD
8.7.1 Overview
8.7.2 SWOT Analysis
8.7.2.1 Strengths
8.7.2.2 Opportunities
8.8 Oxford BioMedica
8.8.1 Business Description
8.8.2 Financial Overview
8.8.3 SWOT Analysis
8.8.3.1 Strengths
8.8.3.2 Weakness
8.8.3.3 Opportunities
8.9 Auron Healthcare GmbH
8.9.1 Company Overview
8.10 AEterna Zentaris
8.10.1 Business Description
8.10.2 Financial Overview
8.10.3 SWOT Analysis
8.10.3.1 Strengths
8.10.3.2 Weakness
8.10.3.3 Opportunities
8.10.3.4 Threats
8.11 Keryx
8.11.1 Business Description
8.11.2 Financial Overview
8.11.3 SWOT Anlaysis
8.11.3.1 Strengths
8.11.3.2 Weakness
8.11.3.3 Opportunities
8.11.3.4 Threats
8.12 Abbott Laboratories
8.12.1 Business Description
8.12.2 Financial Performance
8.12.3 SWOT Analysis
8.12.3.1 Strengths
8.12.3.2 Weaknesses
8.12.3.3 Opportunities
8.12.3.4 Threats
8.13 Pfizer
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.3.1 Strengths
8.13.3.2 Weaknesses
8.13.3.3 Opportunities
8.13.3.4 Threats
8.14 Light Sciences Oncology, Inc
8.14.1 Business Description
8.14.2 Financial Overview
8.14.3 SWOT Analysis
8.14.3.1 Strength
8.14.3.2 Weakness
8.14.3.3 Opportunities
8.14.3.4 Threats

9 Deals Analysis
9.1 Key Highlights
9.2 Key Deals’ Analysis
9.2.1 Eli Lilly Acquires ImClone
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals
9.2.3 Takeda Acquires IDM Pharma
9.2.4 Alchemia Acquires Meditech
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron
9.2.6 BBM Holdings to Acquire YM Biosciences
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis
9.2.8 Peptech Acquires cancer Antibodies from Scancell
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc
9.3 Deals Analysis by Geography
9.4 Deals Analysis by Deal Size

10 Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.3.1 Epidemiology-based Forecasting
Analogous Forecasting Methodology
Diseased Population
Treatment Seeking Population
Diagnosis Population
Prescription Population
Forecasting Model for Therapeutic Areas
10.3.4 Primary Research
10.3.5 Expert Panel validation
10.3.6 Contact Us
10.3.7 Disclaimer
10.3.8 Sources

List of Table

Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010
Table 3: Colorectal Cancer Therapeutics Market, France, Sales Value ($), 2001–2009
Table 4: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009
Table 5: Colorectal Cancer Therapeutics Market, France, Patient Volume (’000), 2001–2009
Table 6: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009
Table 7: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020
Table 8: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020
Table 9: Colorectal Cancer Therapeutics Market, France, Patient Volume (’000), 2009–2020
Table 10: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020
Table 11: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2010
Table 12: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2011-2020
Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010
Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010
Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010
Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010
Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010
Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010
Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010
Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010
Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010
Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010
Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010
Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010
Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010
Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010
Table 28: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010
Table 29: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010

List of Figure

Figure 1: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001-2020
Figure 2: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010
Figure 3: Colorectal Cancer Therapeutics Market, France, Opportunity and Unmet Need, 2009
Figure 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010
Figure 5:  Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010
Figure 6: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2001–2009
Figure 7: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001–2009
Figure 8: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2001–2009
Figure 9:  Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2001–2009
Figure 10: Colorectal Cancer  Therapeutics Market, France, Market Drivers and Restraints, 2009
Figure 11: Colorectal Cancer Therapeutics Market, France, The Impact of  Historical Events on the Market, 2010
Figure 12: Colorectal Cancer Therapeutics Market, France, Sales Value ($bn), 2009–2020
Figure 13: Colorectal Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009–2020
Figure 14: Colorectal Cancer Therapeutics Market, France, Patient Volume, 2009–2020
Figure 15: Colorectal Cancer Therapeutics Market, France, Treatment Usage Patterns, 2009–2020
Figure 16: Colorectal Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009–2020
Figure 17: Colorectal Cancer Therapeutics Market, France, Drug Sales ($m), 2001-2020
Figure 18: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010
Figure 19: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010
Figure 20: Colorectal Cancer Therapeutics Market, France, Sales Forecast Split by Therapies, 2001-2020
Figure 21: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 2004–2010
Figure 22: Colorectal Cancer Therapeutics Market, France, Avastin, Sales Forecast ($m), 2005-2020
Figure 23:  Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 2004–2010
Figure 24: Colorectal Cancer Therapeutics Market, Global, Erbitux, Sales Forecast ($m), 2004-2020
Figure 25: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010
Figure 26: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010
Figure 27: Colorectal Cancer Therapeutics Market, France, Xeloda, Sales Forecast ($m), 2001-2020
Figure 28: Colorectal Cancer Therapeutics Market, Global, Vectibix,  Life Cyle Management Activities, 2010
Figure 29: Colorectal Cancer Therapeutics Market, France, Vectibix, Sales Forecast ($m), 2008-2020
Figure 30:  Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010
Figure 31: Colorectal Cancer Therapeutics Market, Global, Eloxatin,  Life Cyle Management Activities, 2010
Figure 32: Colorectal Cancer Therapeutics Market, France, Eloxatin, Sales Forecast ($m), 2001-2020
Figure 33: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure
Figure 34: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cyle Management Activities, 2010
Figure 35: Colorectal Cancer Therapeutics Market, France, Camptosar, Sales Forecast ($m), 2001-2020
Figure 36: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure
Figure 37: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure
Figure 38: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010
Figure 39: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010
Figure 40: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010
Figure 41: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
Figure 42:  Colorectal Cancer Therapeutics Market, Global,  Technology Trends Description of Pipeline Drugs, 2010
Figure 43: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010
Figure 44:  Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010
Figure 45:  Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010
Figure 46: Colorectal Cancer Therapeutics Market, France, Aflibercept Sales Forecast ($m), 2011-2020
Figure 47: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010
Figure 48: Colorectal Cancer Therapeutics Market, France, Brivanib Sales Forecasts ($m), 2013-2020
Figure 49: Colorectal Cancer Therapeutics Market, France, OncoVAX Sales Forecast ($m), 2011-2020
Figure 50: Colorectal Cancer Therapeutics Market, France, TroVax Sales Forecast ($m), 2014-2020
Figure 51: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010
Figure 52: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010
Figure 53: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2010
Figure 54: Colorectal Cancer, Global, Key Events Impacting the Future Market
Figure 55: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010
Figure 56: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010
Figure 57: Colorectal Cancer Therapeutics Market, Global, Merger and Acqusition Deals by Geography (%), 2010
Figure 58: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010
Figure 65: GlobalData Market Forecasting Model